Stem Cell Clinic

What to eat when you have the flu, recommended by doctors – Business Insider India

When you're sick with the flu, it's no fun trying to figure out what to eat and drink. That's why we've put together a list of doctor-recommended foods and fluids to help.

Water is the best thing you can consume to help you get over the flu. "During an infection, the body's basal metabolic rate increases, which can lead to increased loss of fluids, and you need to increase hydration with water to mitigate these losses," Ian Nelligan, MD, of Stanford Health Care, tells Insider.

As for alternative low-sugar beverages like coffee and tea, opt for caffeine-free. Caffeine can cause headaches and jitteriness, which can make you feel worse, especially if you are combining it with over-the-counter cold and flu medications.

Advertisement

The flu comes with a slew of nasty symptoms, including muscle aches, runny nose, vomiting, and diarrhea. These symptoms not only dehydrate you but deplete you of important nutrients and calories, which are key to fueling your body with the energy it needs to fight the infection.

Yogurt is abundant in protein, calcium, zinc, B vitamins, and Vitamin D, which can help decrease intestinal malfunction. It also contains a number of probiotics, which promote healthy digestion. This might help flu sufferers who are experiencing nausea or vomiting.

Leafy greens, broccoli, and fruits like oranges, strawberries, pineapples, kiwis, and mangoes are a rich source of vitamin C, which studies have shown can reduce the duration of your illness. Vitamin C is also particularly effective at helping fight off the common cold.

Preliminary studies suggest that some other promising remedies include garlic and ginseng, but more scientific evidence is needed for definitive proof that these remedies work for most people.

When you're sick with the flu, you might not feel like doing anything, including eating or drinking. So when push comes to shove, which is more important?

Originally posted here:
What to eat when you have the flu, recommended by doctors - Business Insider India

Fine-Tuning Treatments for COVID-19 – American Council on Science and Health

President Trumps COVID-19 recovery has thrust into the spotlight the possibilities of novel, experimental therapies for this potentially deadly disease. During his stay at Walter Reed National Military Medical Center, he was treated with at least three drugs that have since received substantial attention in the media: the anti-viral remdesivir, the glucocorticoid steroid dexamethasone, and the monoclonal antibody cocktail REGN-COV2.

While evidence suggests these drugs may be effective (and remdesivir just received full marketing approval from the FDA), there are other potential game-changers that have not yet attracted much attention; in fact, almost 2,000 clinical trials of drugs and vaccines (mostly the former) have been registered on the federal governments database. Many of these focus on individuals immune system, either by eliciting an immune response (vaccines) or modulating it, in order that a response is not deleterious.

We Need Vaccines and Therapeutics

While much attention has been paid to the roughlyfive dozen potential vaccine candidatesfor COVID-19 currently in development, even the approval of one or more will not be the end of the COVID-19 pandemic saga. First of all, no vaccine is 100% effective, able to prevent infection, or even symptoms, in all recipients. (The overall average for flu vaccines is 40-60%, while for the first shingles vaccine, it was about 70%).

But as I discussed in a recent article, even an excellent vaccine is no good if no one takes it, and surveys have found significant resistance. A Kaiser Family Foundationpollpublished last month found that only about 42% of Americans would opt for a free COVID-19 vaccination before the presidential election.A similar result emerged from a more recentsurveyby Morning Consult, which found that only 38% would get a coronavirus vaccine if one became available. Those data are in line with the poor uptake of other vaccines intended for adults.

If the poll numbers hold up, even after vaccines are available, we could see continuing high levels of COVID-19 infections, with sporadic surges above baseline. It has been estimated that we will need immunity in roughly70% of the population, through either natural infection or vaccine administration, in order to achieve herd immunity, or community immunity, which occurs when a sufficiently large portion of a community (the herd) becomes immune to a disease that the spread of disease from person to person becomes unlikely.That protects the whole community not just those who are immune.Clearly, we will never even approach that, if a significant fraction of the population rejects the vaccine. Thus, there will be an ongoing need to wear masks, for social distancing, avoidance of crowds indoors, and also for better drug treatments for people who do become infected.

The Immune Response: Too Little or Too Much?

The immune system wanes as people age, resulting in a diminished ability to fight off infections or to mount a vigorous immune response to vaccines hence, the high mortality rate in patients with COVID-19 and the special, higher-dose versions of flu vaccine for seniors. However, in many patients with severe COVID-19, the bodys own exaggerated immune response can be just as damaging if not more so than the virus itself. It can take several forms, including injury to the endothelium (i.e., the cells lining the inside of blood vessels), cytokine storm (the uncontrolled release of proinflammatory proteins, as part of the immune response), or excessive coagulation. These can lead to life-threatening acute respiratory distress syndrome (ARDS) and multi-organ damage. Studies conducted earlier this year showed that the nucleocapsid, or N-protein, of SARS-CoV-2 is involved in activating the lectin pathway, an essential part of the complement system, which provides an organisms effective defense against invading pathogens. The lectin pathway itself is also a proteolytic cascade of molecular events that gives rise to, among other things, the adaptive immune response.

More specifically, a group of Chinese researchers found in studies in mice that the N-proteins of SARS-CoV-2 and other highly pathogenic coronaviruses bind to MASP-2, the key serine protease in the lectin pathway of complement activation, which results in aberrant complement activation and severe inflammatory lung injury. This N-protein-induced complement hyper-activation was also observed in COVID-19 human patients, and a promising suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody. Therefore, they concluded that, Complement suppression may represent a common therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses.

A promising drug candidate that targets this pathway is a monoclonal antibody called narsoplimab that blocks the MASP-2 enzyme and inhibits activation of the lectin pathway. By blocking the activation of this part of the bodys immune system, narsoplimab should dampen the impact of the overactive immune response and prevent a dangerous cascade of complications including coagulation and blood clots, while leaving the anti-infection activity of the adaptive immune response intact.

Narsoplimab is currently being evaluated by the FDA to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase 3 clinical trials in IgA nephropathy and atypical hemolytic uremic syndrome. FDA has granted the drug breakthrough therapy designation for both HSCT-TMA and IgA nephropathy. Since injury to endothelial cells (the cells that line blood vessels) is central to the pathophysiology of both COVID-19 infection and HSCT-TMA, the drugs potential to help treat COVID-19 patients is promising. A peer-reviewed studyconducted by Italian and American doctors in Bergamo, Italy an early COVID-19 hotspot suggests that narsoplimab could be an effective treatment for critically ill COVID-19 patients with ARDS and multi-organ disease in patients requiring mechanical ventilation. After two to four weeks of treatment, all six patients in the study recovered and were discharged from the hospital after showing a sustained reduction in all assessed markers of endothelial damage, inflammation, and coagulation. Further, researchers reported no drug-related adverse reactions from any patients in the study and also suggested that two of the patients who had massive bilateral pulmonary thromboses may have benefited from narsoplimabs anticoagulant effects.

Due to the emergent nature of narsoplimabs use in Bergamo, the administration of the drug was not performed as part of a formal, prospective, controlled clinical trial, and the physicians were only able to compare the patients to a control group retrospectively, with the controls showing mortality in excess of 50%. The growing body of literature on the need to stop the cascade of complement activation, coagulation, and inflammation suggests the need for further research on this promising approach to COVID-19, especially in sicker patients in jeopardy of, or experiencing, cytokine storm.

We might, indeed, have to live with COVID-19 infections at some level in the community for the foreseeable future, but it should be with as few hospitalizations and deaths as possible. Therefore, moving forward, the research community should pursue every promising drug and vaccine candidate.

Read more here:
Fine-Tuning Treatments for COVID-19 - American Council on Science and Health

Aborted girl fetus kidneys made Trumps CoV meds. As SARS2 is unfettered in America, this needs thought – Feminine-Perspective Magazine (FPMag)

In order to produce the medication that maybe saved Donald Trumps life, an unborn baby girl died in an abortion. This fetus had to be one that had kidneys.

Not much is said about Trumps unapproved monoclonal antibody cocktail perhaps because in mid-August of this year, more than a month before Trump took sick with COVID-19, Trump kyboshed fetal tissue research.

The Trump Administration-appointed (Feb. 2020) Human Fetal Tissue Research Ethics Advisory Board of 15 persons, mostly anti-abortionists, banned just about everything that used fetal cells, in any quantum, from being used in research projects. Some fourteen proposals out of fifteen were quashed.

Editorial science comment, by Micheal John

Click to enlarge. Immunofluorescent Human Embryonic Kidney 293 cells. Phospho-Histone H3 (yellow), phalloidin (green), nuclei (red). Photo Credit: Iznewton, CC BY-SA 4.0,

The medical research community was nearly apoplectic claiming the Human Fetal Tissue Research Ethics Advisory Board is bogus with absolutely no proper scientific credentials to make such edicts.

US Health Secretary Alex Azar must take the final call, however none of the sources FPMag spoke with had any doubt of the Human Fetal Tissue Research Ethics Advisory Board getting its decisions approved.

Anti-abortion is a fundamental tenet of the Republican Party. But Trump is alive perhaps because of research that initially used fetal tissue.

Trump is a con artist, a grifter, a liar. People who dont realize that are vulnerable to falling into the category of mark, sucker, or in Trumps own words, one of the losers who falls for his cons. Consumer advocates call this type of person Trump calls losers as the credulous citizen. They are vulnerable to things like false advertising and bogus products. Its a challenge keeping the Pied Pipers following from marching into a deadly cliff fall and today there are laws against being a Pied Piper of ill will.

Hence it doesnt really matter about the politics or personal moraliity of Trumps monoclonal antibody cocktail derived from fetal tissue research. It doesnt matter to him, and whatever spin Trump puts on it is how his top will twirl. How do normal people deal with this morality issue?

If a baby died during an abortion on demand, and the babys cells were used to save dozens of lives, there is still no equity in that. Thou shall not kill. But if the procedure (induced abortion) was not elective, dont waste a single cell if the parents are willing to donate tissue for scientific research just like an organ donor would do on their drivers license. That was the consensus of a half dozen doctors and nurses of The RINJ Foundation.

Read if you wish: Report of the Human Fetal Tissue Research Ethics Advisory Board FY2020.

The incipient cells in a laboratory growth Donald Trumps COVID-19 momoclonal antibody cocktail was derived from, were human embryonic kidney cells grown in a tissue culture from an aborted female fetus.

These cells have many names but the most precise name of the origin is HEK293.

HEK 293 come from aborted female fetus kidneys originally but can reliably reproduce and produce variations in a laboratory in a worthwhile quantity and many generations away from origin. Dozens of genetic sequences exist for research purposes.

The question of importance, is how many dead baby girl fetuses does it take to manufacture Regenerons REGN-COV2 monoclonal drugs, or any such drugs for COVID-19 in enough quantity to give an unknown percentage of 8 billion people the doses they would need. The answers to any of these questions are only wild guesswork until research has concluded with due approvals.

Remember that Remdesivir (Veklury), is an antiviral medication developed by Gilead Sciences, to be initially used as an Ebola remedy. Now Remdesivir has been cited in many good outcomes when used as a COVID-19 treatment. Anti-viral pharmacological research has a long way to go.

Stay out of the way of progress, is good advice.

If induced abortion is not seen for what it is, a medical procedure; and abortion as a form of birth control is not perceived as murder; the potential of HEK293 could be lost in foolish arguments by credulous people led by charlatans.

Stem cell research and fetal tissue research need to come out of the shadows.

Natural abortions happen; legitimate case-indicated induced abortions also happen.

Human kind is beyond tissue and organ donations, we need to get past this one. Either we select and train doctors so that they are trusted, or we agree that has been achieved and trust our medical practitioners to make the right calls. Making abortion laws is a fools game. It is a sometimes needed medical procedure, and a doctor/patient callsometimes only the doctor. Law or no law, it is that way. Doctors save the lives they can save.

In the meantime, Regenerons REGN-COV2 monoclonal drugs for COVID-19 are for the bigwigs, like Trumpvery expensive too.

Even after a SARS2 viable vaccine is approved and vaccinations begin, millions of people will still get sick from SARS-CoV-2 infection and too many will die. Hence a reliably effective treatment is needed. Hold nothing back if it has promise. This pathogen could with a little help from its hosts, wipe out much of the human race.

I suppose a cynical future historian might look at Trump rallies and suggest that COVID-19 killed all the credulous people, the stupid ones who ignored the warnings. They were told: socially distance themselves from others, stay home, wear a mask to go shopping, and keep clean. The evidence of quasi-suicidal behaviour at these superspreader events is in reams of video footage and still photographs. Dr. Sanjay Gupta of CNN did a study of many events and found that 82% had a surge in COVID-19 cases within a few weeks. The warnings were correct.

Some drugs are proving very useful from the common acetylsalicylic acid, to the also common famotidine heartburn medication. Clonidine seems to block cytokine storms in patients who already take this antihypertensive medication and some steroids have proven useful also for blocking the runaway immune systems in very sick patients. These are the direct experiences of the writer in running various medical clinics around the world. Still no one therapy is perfect for every patient. Compared to what we need to know, medical science knows relatively nothing about the SARS-CoV-2, but the learning process is ongoing and driven.

As the most vulnerable people in society are killed off by the virus, and as better treatments are derived learning from experience, SARS2 is killing a smaller percentage of the infected population. (Vulnerable persons must never be in circulation without an N95 mask. Absolutely never.)

Read back over this article. Think to yourself about the level of intelligence that it will take to solve some of these problems. Consider that COVID-19 may be a mere molecule on the tip of the spear that is coming at the human race.

The level of gray matter needed to solve these complex social, political and scientific issues is not possessed by the middle to lower echelons of the intelligence scale that men like Bolsonaro, Modi and Trump appeal to as populists. Better government is needed than these utter fools. Look for yourself. This pie chart is not just revealing, it is disgusting evidence of at least sociopathy and likely even greater ails at the top. Nearly two billion good people suffer the psychopathy of three you-know-whats.

The following graph shows daily excess deaths, likely directly or indirectly caused by COIVD-19. In any case they are deaths above normal and about 1.29x (in the current period) of the reported deaths from COVID-19. These are the real numbers of Americans who died in excess of the normal number of deaths from other causes.

Link:
Aborted girl fetus kidneys made Trumps CoV meds. As SARS2 is unfettered in America, this needs thought - Feminine-Perspective Magazine (FPMag)

What to Know in Washington: Provisional Ballots May Play Role – Bloomberg Government

If the U.S. is still waiting to learn who the president will be days or even weeks after Tuesdays election, provisional ballots are likely to be at the center of any disputes.

They are the ballots cast by voters whose eligibility is questioned for some reason. Those ballots are set aside and held for a period of days after the election while workers determine whether they should be counted.

Experts say the number of provisional ballots this year may set a record, exceeding the 2.7 million cast in 2012 and almost 2.5 million cast in 2016, in part because some voters who requested ballots by mail are showing up at polls to vote in person. That could lead to late results in key battleground states such as Pennsylvania where President Donald Trump won by only 44,292 votes in 2016 if the race is close and the source of challenges and litigation.

Its just another one of those things that plays into the unusual nature of this election, G. Terry Madonna, director of the Center for Politics and Public Affairs at Franklin and Marshall College in Pennsylvania, said of provisional ballots.

Provisional ballots have come into play in the past. Democrat John Kerry held off conceding the 2004 presidential race to Republican George W. Bush until the morning after the election because he waited until it was clear the 157,714 provisional ballots cast in Ohio couldnt change the outcome.

In 2016, Trump carried Arizona by 91,234 votes, and there were 102,510 provisional ballots, according to the U.S. Election Assistance Commission. Pennsylvania had 26,451 provisionals, and that was before the commonwealth expanded voting by mail last year.

Greater use of mailed ballots, coupled with disruptions in mail service, may contribute to the bumper crop of provisional ballots. After initially urging voters to request mail-in ballots in response to the pandemic, Democratic leaders have been telling people to vote in person or deliver the ballot to an elections office or an approved drop box to avoid the risk of it being disqualified on technical grounds or having its delivery delayed by the U.S. Postal Service. Read more from Mark Niquette.

Photographer: David Paul Morris/Bloomberg

Voters who requested mail-in ballots but opt to vote in person could lead to more provisional ballots.

USPS Cites Covid, Holiday for Record Delays: The U.S. Postal Service delivered 80.85% of first-class mail on time for the week ending Oct. 23, compared with previous weeks figure of 85.58%, according to a news release. The agency listed factors including high mail volume, Covid-19 impacts, the Oct. 12 federal holiday and ongoing efforts to prioritize ballots for the Nov. 3 election. The on-time rate is the lowest of the year, according to the Save the Post Office website that tracks the agency. Read more from Todd Shields.

BGOVs Downballot Races to WatchReddit AMA: Join Bloomberg Governments elections guru Greg Giroux this afternoon on Reddit for an AMA on the congressional elections, where hell take questions on the races to watch. Follow his AMA here at 2 p.m. today.

Biden Win Would Offer Path to Kill Pipeline: Days after taking office, Trump cleared the way for construction of an oil pipeline in the Midwest that had been the focus of months of opposition by climate activists, celebrities and Native Americans. Now opponents of the Dakota Access Pipeline are pressuring Joe Biden to take the extraordinary step of returning the favor should he win the White House. Analysts said they couldnt recall a president shutting down an operating pipeline before, which is why its being viewed as a litmus test of how far hed go to appease environmentalists who have supported him. Read more from Ari Natter.

Biden Pledges Not to Extort South Korea: Biden pledged not to use the threat of cutting U.S. troop levels in South Korea as a bargaining chip, after the Trump administration demanded Seoul pay far more for American protection. Biden said if he wins the U.S. election next week, he wont be extorting Seoul with reckless threats to remove our troops, according to a special contribution he made to South Koreas Yonhap News Agency published today. Read more from Jon Herskovitz.

Trumps China Scorecard Shows Many Defeats: Trump ran for office pledging to rewrite the U.S.s economic ties with Beijing, which he blamed for hollowing out Americas manufacturing base and impoverishing its workers. But his four years in the White House have shown limited impact on the metrics he laid out. U.S. companies cite much the same concernsand the same growth objectiveswith regard to China today as they did when Trump took office. The unprecedented trade war that Trump launched, breaking GOP free-trade orthodoxy along the way, has ended up costing American factory jobs, not creating them, economists claim. The state support for Chinese enterprises that Trump pledged to confront remains intact.

Trumps term has, however, had a notable impact on American attitudes toward China. In time, that could prove the dynamic that affects economic ties in ways the current president has struggled to achieve. And it underscores that Washingtons policy on China is forever changed, regardless of who wins next Tuesdays election. Read more from Jenny Leonard.

Health-Care on the Ballot in Several States: Big money is betting on health-care initiatives in California, Oregon, and Colorado where voters are being asked Nov. 3 to add taxes on vaping, mandate that doctors always be on site when dialysis centers are open, and approve $5.5 billion in bonds for the sole stem cell research funding agency in the country. Tens of millions of dollars are fueling arguments over what to fund and why because, essentially, people are more interested in health-care initiatives, said Arturo Vargas Bustamante, associate professor in the Department of Health Policy and Management at the University of California, Los Angeles. Read more from Joyce E. Cutler.

Gerrymander Power on the Line: A shift toward independent redistricting commissions helped spur national political parties to spend record cash in the hope of controlling the next congressional redistricting. The outcomes in just a few races in a few states will determine the Republican Partys chances of winning congressional majorities for the next decade. And were fighting like hell to win, Republican State Leadership Committee President Austin Chambers said in an email. His group raised $23 million in the third quarter and is targeting 115 districts that could hold the keys to a 136-seat swing in the U.S. House.

Democrats are fighting money with money. The Democratic Legislative Campaign Committee has pledged to spend $50 million in state races this cyclemore than six times what it spent in 2010. Read more from Alex Ebert.

Biden Courts Latino Voters as Tie-Breakers: Biden appealed to Hispanic voters in Florida, a closely divided battleground state where a win next week would give him the presidency. The heart and soul of the country is at stake right here in Florida. Its up to you. You hold the key. If Florida goes blue, its over, Biden said in a neighborhood in Broward County, which stretches south from Fort Lauderdale toward Miami and is a key source of Democratic votes in the state. Read more from Jennifer Epstein.

Facebook Says Technical Hiccups Improperly Blocked Campaign Ads: Facebook revealed yesterday how internal technical glitches disrupted the delivery of some ads from the Biden and Trump campaigns, but said it made changes to resolve those hiccups in the run-up to the November election. The social media giants admission followed complaints from the Biden camp about how thousands of its ads were blocked. Facebook said in a blog post it spotted unanticipated issues affecting both campaigns, including technical flaws that caused a number of ads to be paused improperly. Read more from Sarah Frier.

Trumps Social Media Order Defeats Legal Challenge: The Trump administration defeated a challenge by Rock the Vote and Voto Latino to a recent executive order targeting social media companies that fact-check the presidents posts about the election, when a federal judge said yesterday that the get-out-the-vote groups lacked standing to bring the case. Judge William H. Orrick said the groups couldnt show the order regulated Facebook, Twitter, or another social media website in any way or credibly threatened them with prosecution. Read more from Mike Leonard.

BGOV OnPoint: Section 230 Internet Shield Faces Bipartisan Attacks.

Zeta Disrupts Early Voting in Georgia: Hurricane Zeta caused disruptions to early voting across the South yesterday, including in the key battleground states of Georgia and North Carolina. Zeta, now a tropical storm, knocked out power to more than 1 million homes and businesses as early in-person voting enters a final stretch with five days to go until Election Day. Friday is Georgias last day to vote while voters in North Carolina have until Saturday. Read more from Misyrlena Egkolfopoulou and Joe Ryan.

More Hawaiians Voted Early Than All of 2016: Early voting in Hawaii has already surpassed the total number of ballots cast in the state in the 2016 election. Data from the U.S. Elections Project, which tracks early voting, found Hawaii has seen turnout hit 104.5% of its total from the last election. More than half of all registered voters in Hawaii have already sent in their ballots, topping the record for the total number of votes cast in the state for a general election. Read more from Emma Kinery.

U.S. Sets Daily Virus Case Record: New U.S. cases topped 86,000, setting a new daily record, as the outbreak intensifies ahead of next weeks presidential election. Read more from Bloomberg News.

U.S. Buying Gowns from Untested Makers: Several U.S. companies that won almost half a billion dollars in government contracts to make hospital gowns appear to have too few workers and not enough factory space to complete the job when the awards were made, according to a Bloomberg Law analysis. At least 11 contractors and subcontractors began making protective gear only after the pandemic began, according to press releases and news reports. Of the 15 primary contractors, eight had never received a federal contract prior to 2020, according to federal government contracting records. The Defense Department says contractors went through a rigorous process and met stringent criteria.

Still, members of Congress are raising questions. Some of those contracts have been to companies that have very little experience with producing that kind of equipment, that the standards have not always been up to par, and its created some real challenges, Sen. Jeanne Shaheen (D-N.H.) said during a Senate Armed Services committee hearing Oct 1. Read more from Shira Stein.

Covid Relief Laws May Bolster ACA Legal Case: Republicans may have hurt their own legal case against Obamacare by repeatedly expanding on and amending the signature health law since 2017, most recently in their response to the coronavirus pandemic. You cant build on the ACAs protections for the Covid bills if the act doesnt exist, said Abbe Gluck, a professor of law and the founding faculty director of the Solomon Center for Health Law and Policy at Yale Law School.

The U.S. Supreme Court will assess legal arguments on the constitutionality of the Affordable Care Act on Nov. 10. What Congress intended to do with the ACA is a central line of dispute in the high stakes case, and the pandemic has given supporters of the law a new opportunity to prove it was meant to stay. Read more from Lydia Wheeler.

New Projection Shows Higher Death Toll: The Institute for Health Metrics and Evaluation, an influential modeling group, is projecting a higher death toll in the U.S. amid the surge in Covid cases and hospitalizations. The group is now projecting about 405,000 deaths due to the virus by Feb. 1, representing a nearly 20,000 increase from a prior projection of 386,000. Europe is seeing a surge right now and Europe is ahead about a month from the United States, said Ali Mokdad, a professor of health metrics sciences with IHME. So basically we are watching what would unfold here in the United States. Read more.

CDC Evictions Moratorium Upheld by Judge: A federal judge ruled against landlord groups trying to block the U.S. Centers for Disease Control and Preventions national moratorium on evictions amid the coronavirus crisis. U.S. District Judge J.P. Boulee in Atlanta yesterday rejected a motion for a preliminary injunction brought by the New Civil Liberties Alliance and National Apartment Association, which represents some 85,000 landlords responsible for 10 million rental units. The judge said the public interest in curtailing the spread of Covid outweighed the landlords economic interest. Read more from Chris Dolmetsch.

Trump Rule Leads Contractors to Cut Training: Trumps recent attempt to curb corporate diversity training will linger even if he loses Tuesdays election to Biden. Already, federal contractors are unsure of what they can say about race. More than 300 events, training programs, research projects and other diversity-related activities have been delayed or canceled because of concern about a Sept. 22 executive order aimed at banning federal contractors and agencies from using terms in diversity training that the administration considers divisive and illegal, according to the African American Policy Forum, a social justice think tank. A Labor Department official said last week that the agencys already received more than 100 complaints via a government hotline to report possible violations. Read more from Paige Smith and Jeff Green.

Hackers Plan More Attacks on U.S. Hospitals: A Russia-based ransomware group responsible for a new wave of attacks against U.S. hospitals is laying the groundwork to cripple at least ten more, according to the cybersecurity firm Prevailion. Prevailions analysis comes a day after the FBI and two other federal agencies issued a warning about an imminent and credible threat to hospitals and health-care providers from cyberattacks, including ransomware capable of locking entire computer networks. The hacking group responsible has already hit at least nine hospitals in three weeks, crippling critical computer systems and demanding multimillion-dollar ransoms. Read more from Alyza Sebenius, William Turton and Michael Riley.

Insurers Must Post Out-of-Pocket Medical Costs: Health insurers will have to post on the internet personalized out-of-pocket costs to patients under a new rule finalized yesterday. Insurance plans will also be required to make their in-network negotiated rates with doctors and allowable out-of-network rates available to the public, according to the multiagency rule. They will be required to post their negotiated pharmaceutical prices and the historical net prices for all their covered drugs. Read more from Shira Stein, Lydia Wheeler and John Tozzi.

How the Google Case Could Play Out: Google and the Justice Department are set to face each other in court today for the first time since the government sued the company for illegally monopolizing internet search. The hearing marks the first time attorneys for Google and the government will come together to start mapping out the the litigation process. It will set the stage for whats shaping up to be a drawn-out court battle that could ultimately weaken Googles gatekeeper position over the web if the government is successful. Vicky Graham lays out how to follow the case as it winds its way through federal court.

737 Jet Crash Victims Demand U.S. Records: The relatives of the 157 people who died in the crash of a Boeing 737 Max in Ethiopia are demanding more records from U.S. safety agencies, according to a pair of letters sent on the second anniversary of another accident involving the plane. A letter to the National Transportation Safety Board, which assisted in the investigation of both crashes, accused it of an unreasonable pro-secrecy stance. Alan Levin has more.

Gray Wolf Protections Stripped, Stirring Lawsuit Threats: The Interior Department announced yesterday it will strip endangered species protections from the gray wolf. Environmental groups vowed to challenge the decision in court, saying it violates the Endangered Species Act by ignoring the best available science. If Democrat Joe Biden wins the presidency, his administration could seek to overturn the move. Todays action reflects the Trump administrations continued commitment to species conservation based on the parameters of the law and the best scientific and commercial data available, said Interior Secretary David Bernhardt. Stephen Lee and Kellie Lunney have more.

Administration Appeals Court Order on Visa Ban: The Trump administration is appealing a California federal courts Oct. 1 ruling that blocked the departments of State and Homeland Security from barring entry to the U.S. for certain temporary work visa holders. In their filing, U.S. Justice Department lawyers signaled theyll ask the San Francisco-based U.S. Court of Appeals for the Ninth Circuit to reinstate Trumps proclamation in full, Genevieve Douglas reports.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com; Michaela Ross at mross@bgov.com

The rest is here:
What to Know in Washington: Provisional Ballots May Play Role - Bloomberg Government